Publication: NILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES
Loading...
Program
relationships.isAuthorOf
Author
Yavuz, Akif Selim
Elcioglu, Oemer Celal
Cosan, Fulya
Ucur, Ali
Bayrak, Ayseguel
Cefle, Kivanc
Oeztuerk, Suekrue
Palanduz, Suekrue
Yenerel, Mustafa Nuri
Advisor
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Objective: Clonal cytogenetic aberrations other than Philadelphia chromosome can develop during the course of chronic myeloid leukemia naturally or under the pressure of treatment strategies like interferon, imatinib and dasatinib. Some of them are associated with resistance to treatment and progression to advanced phases of chronic myeloid leukemia. Nilotinib is a second generation thyrosine kinase inhibitor, but its efficacy in chronic myeloid leukemia patients with additional chromosomal changes has not been delineated yet. In this study we evaluated the efficacy of nilotinib in imatinib-resistant or -intolerant t(9;22) positive chronic myeloid leukemia patients with and without additional chromosomal changes
Description
Source
Keywords
Keywords
Citation
Yavuz A. S. , Elcioglu O. C. , Akpinar T., Cosan F., Ucur A., Bayrak A., Cefle K., Oeztuerk S., Palanduz S., Yenerel M. N. , et al., -NILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES-, NOBEL MEDICUS, cilt.6, ss.57-62, 2010